References
- Mountain CF. Lung cancer staging classification. Clin Chest Med 1993; 14(1): 43–53
- Rusch VW. Resection of stage III non-small cell lung cancer following induction therapy. World J Surg 1995; 19(6): 817–22
- Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage III a (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55(6): 1365–73
- Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330(3): 153–8
- Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86(9): 673–80
- Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323(14): 940–5
- Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small- cell lung cancer. N Engl J Med 1992; 326(8): 524–30
- Veeder MH, Jett JR, Su JQ, et al. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 1992; 70(9): 2281–7
- Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311 (7010):899–909
- Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carbo- platin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13(8): 1860–70
- Miller VA, Rigas JR, Grant SC, et al. New chemotherapeutic agents for non-small cell lung cancer. Chest 1995; 107(6 Suppl): 306S–11S
- Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small- celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 1973; 2(820): 63–5
- Jett JR, Everson L, Therneau TM, et al. Treatment of limited- stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol 1990; 8(1): 33–8
- McCracken JD, Janaki LM, Crowley JJ, et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol 1990; 8(5): 892–8
- Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 1994; 5(7): 601–7
- Arriagada R, Pignon JP, Ihde DC, et al. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A metaanalysis of 13 randomized trials among 2,140 patients. Anticancer Res 1994; 14(1B): 333–5
- Medical Research Council Lung Cancer Working Party. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989; 59(4): 584–90
- European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 1993; 11 (7): 1230–40
- Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83(12): 855–61
- Ettinger DS. The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update. Semin Oncol 1995; 22(1 Suppl 2): 23–7